Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial
Study context
- Population
- Adults aged ≥40 with obesity or overweight (BMI ≥27.0 kg/m²), without diabetes, with established CVD or multiple cardiovascular risk factors; 664 sites across 27 countriesplanned enrolment
- Participants
- ≈15,000 adults
- Planned comparison
- Once-weekly tirzepatide vs placebo
- Primary endpoint
- Time to first occurrence of a five-component composite of:
- Nonfatal MI
- Nonfatal stroke
- Coronary revascularization
- HF events
- Death from any cause
Methodological detailsdouble-blind, event-driven, placebo-controlled, multinational
- Double-blind
- Event-driven
- Placebo-controlled
- Multinational
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity (Silver Spring). Published 22 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →